Table 1 Baseline characteristics of UK Biobank participants by sex-specific quintiles of serum urate
From: Serum urate and lung cancer: a cohort study and Mendelian randomization using UK Biobank
Total | Quintile of serum urate (µmol/L) | |||||
|---|---|---|---|---|---|---|
Men | 89–294 | 295–332 | 333–367 | 368–411 | 411–600 | |
Women | 89–215 | 216–248 | 249–279 | 280–321 | 322–600 | |
N = 359,192 | N = 71,716 | N = 71,889 | N = 71,745 | N = 71,927 | N = 71,915 | |
Sex | 166,618 (46.4%) | 33,296 (46.4%) | 33,320 (46.3%) | 33,278 (46.4%) | 33,380 (46.4%) | 33,344 (46.4%) |
Age at recruitment (IQR) | 58.9 (51.3–64.0) | 57.3 (49.4–63.1) | 58.1 (50.3–63.5) | 58.7 (51.3–63.8) | 59.5 (52.3–64.2) | 60.5 (53.7–64.9) |
Weight (kg) | 78.3 (15.8) | 72.3 (14.0) | 75.1 (14.5) | 77.7 (14.9) | 80.6 (15.5) | 85.8 (16.5) |
Height (cm) | 168.8 (9.2) | 169.0 (9.0) | 169.0 (9.1) | 168.9 (9.2) | 168.8 (9.3) | 168.4 (9.4) |
BMI | 27.4 (4.7) | 25.2 (3.9) | 26.2 (4.0) | 27.1 (4.2) | 28.2 (4.6) | 30.2 (5.2) |
Smoking status | ||||||
Never | 195,303 (54.4%) | 41,107 (57.3%) | 40,526 (56.4%) | 39,585 (55.2%) | 38,386 (53.4%) | 35,699 (49.6%) |
Former | 126,440 (35.2%) | 21,763 (30.3%) | 23,462 (32.6%) | 24,988 (34.8%) | 26,581 (37.0%) | 29,646 (41.2%) |
Current | 36,227 (10.1%) | 8622 (12.0%) | 7654 (10.6%) | 6951 (9.7%) | 6726 (9.4%) | 6274 (8.7%) |
Missing | 1222 (0.3%) | 224 (0.3%) | 247 (0.3%) | 221 (0.3%) | 234 (0.3%) | 296 (0.4%) |
Pack years of smoking (IQR)* | 19.5 (10.0–32.5) | 18.8 (9.3–31.5) | 18.0 (9.0–30.6) | 18.8 (9.5–31.5) | 19.5 (10.1–32.5) | 22.0 (12.0–35.5) |
History of lung cancer | 528 (0.15%) | 101 (0.14%) | 82 (0.11%) | 98 (0.14%) | 91 (0.13%) | 156 (0.22%) |
Family history of lung cancer | 46,291 (12.9%) | 8547 (11.9%) | 8738 (12.2%) | 9218 (12.8%) | 9596 (13.3%) | 10,192 (14.2%) |
History of COPD/emphysema | 8167 (2.3%) | 1486 (2.1%) | 1458 (2.0%) | 1515 (2.1%) | 1646 (2.3%) | 2062 (2.9%) |